Evidence map›Paper›PMID 40313620›Full record

ArticleFrontiers in pharmacology2025

The pharmacokinetics and Concentration-QTc analysis of a new etomidate analog ET-26-HCl: a phase I trial in healthy Chinese subjects.

Kun He, Wenyu Zhang, Xiangran Kong, Lize Li, Lei Diao, Qing Wen, Guohai Su, Xiaoran Yang, Hongyan Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kun HeDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Wenyu ZhangDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xiangran KongDepartment of Cardiovascular Medicine Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Lize LiAvanc Pharmaceutical Co., Ltd., Jinzhou, China.
Lei DiaoShanghai Fosun Pharmaceutical Development Co. Ltd., Shanghai, China.
Qing WenDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Guohai SuDepartment of Cardiovascular Medicine Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xiaoran YangAvanc Pharmaceutical Co., Ltd., Jinzhou, China.
Hongyan ZhaoDepartment of Cardiovascular Medicine Central Hospital Affiliated to Shandong First Medical University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methoxetamine hydrochloride (ET-26-HCl) is a novel short-acting intravenous general anesthetic that retains the advantages of etomidate while minimizing its impact on adrenal cortical function. A single-center, randomized, open-label, placebo-controlled clinical trial was conducted using concentration-QTc (C-QTc) model analysis to evaluate the pharmacokinetics, clinical sedative effect, safety, and potential risk of QT interval prolongation of ET-26-HCl at doses of 0.8 mg/kg (the clinical dosage) and 2.8 mg/kg. In the 0.8 mg/kg group, the mean peak concentration ( Clinical Trials Registration Number: ClinicalTrials.gov CTR20233230.

Indexed as

C-QTc modelingetomidate acidmethoxyetomidate hydrochloridepharmacokineticsQTc effect

Identifiers

PMID40313620
PMCPMC12043489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.